Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H22N4.2ClH |
| Molecular Weight | 319.273 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.Cl.[H][C@]12CCCN(CCC)[C@]1([H])CC3=C(C2)N=C(N)N=C3
InChI
InChIKey=WDEMLQIGYYLRRX-OWVUFADGSA-N
InChI=1S/C14H22N4.2ClH/c1-2-5-18-6-3-4-10-7-12-11(8-13(10)18)9-16-14(15)17-12;;/h9-10,13H,2-8H2,1H3,(H2,15,16,17);2*1H/t10-,13-;;/m1../s1
| Molecular Formula | C14H22N4 |
| Molecular Weight | 246.3513 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Quinelorane is an octahydropyrimido[4,5-g]quinolone derivative patented by American pharmaceutical company Eli Lilly and Co. as for the treatment anxiety, Parkinson's syndrome, depression, and hypertension. Quinelorane acts as an agonist of dopamine agonist for the D2 and D3 receptors. In preclinical studies Quinelorane (IM) treatment produced dose-dependent effects on male sexual responding. Penile erections and masturbation were markedly facilitated following treatment with either 2.5 or 5 micrograms/kg quinelorane. Higher doses of quinelorane (10 and 25 micrograms/kg) generally did not further augment sexual responding but rather resulted in a return in sexual responding to control vehicle levels. Quinelorane had a biphasic effect on yawning behavior of the monkeys with low doses (2.5 and 5 micrograms/kg) facilitating yawning and high doses (25 micrograms/kg) inhibiting yawning.
CNS Activity
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Observations on the absorption, distribution, metabolism, and excretion of the dopamine (D2) agonist, quinelorane, in rats, mice, dogs, and monkeys. | 1991 Jan-Feb |
|
| Evidence to suggest that agonist modulation of hyperlocomotion is via post-synaptic dopamine D2 or D3 receptors. | 1997 Jun |
|
| Effects of dopamine D(1-like) and D(2-like) agonists in rats that self-administer cocaine. | 1999 Oct |
|
| Role of dopamine D3 receptors in thermoregulation: a reappraisal. | 2000 Jan 17 |
|
| Previous exposure to amphetamine enhances the subsequent locomotor response to a D1 dopamine receptor agonist when glutamate reuptake is inhibited. | 2001 Mar 1 |
|
| Dopamine D1/5 receptor stimulation induces c-fos expression in the subthalamic nucleus: possible involvement of local D5 receptors. | 2002 Jan |
|
| Gradient of dopamine responsiveness to dopamine receptor agonists in subregions of the rat nucleus accumbens. | 2003 Sep 12 |
|
| Quantification and pharmacological characterization of dialysate levels of noradrenaline in the striatum of freely-moving rats: release from adrenergic terminals and modulation by alpha2-autoreceptors. | 2004 Dec 30 |
|
| Modulation of the locomotor activating effects of the noncompetitive NMDA receptor antagonist MK801 by dopamine D2/3 receptor agonists in mice. | 2004 Feb |
|
| Neuromodulation of the locomotor network by dopamine in the isolated spinal cord of newborn rat. | 2004 Mar |
|
| A reconfiguration of CaV2 Ca2+ channel current and its dopaminergic D2 modulation in developing neostriatal neurons. | 2005 Dec |
|
| Delta-9-tetrahydrocannabinol differentially suppresses emesis versus enhanced locomotor activity produced by chemically diverse dopamine D2/D3 receptor agonists in the least shrew (Cryptotis parva). | 2005 Jan |
|
| Yawning and hypothermia in rats: effects of dopamine D3 and D2 agonists and antagonists. | 2007 Aug |
|
| Quinelorane, a dopamine D3/D2 receptor agonist, reduces prepulse inhibition of startle and ventral pallidal GABA efflux: time course studies. | 2008 Oct |
|
| Neural basis for a heritable phenotype: differences in the effects of apomorphine on startle gating and ventral pallidal GABA efflux in male Sprague-Dawley and Long-Evans rats. | 2009 Dec |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 18:00:41 GMT 2023
by
admin
on
Fri Dec 15 18:00:41 GMT 2023
|
| Record UNII |
JT5527J55O
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C66884
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
C152122
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY | |||
|
68728
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY | |||
|
DTXSID60913869
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY | |||
|
CHEMBL155731
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY | |||
|
97548-97-5
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY | |||
|
X-99
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY | |||
|
JT5527J55O
Created by
admin on Fri Dec 15 18:00:41 GMT 2023 , Edited by admin on Fri Dec 15 18:00:41 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |